Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)

Trial Profile

Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Acronyms RIG
  • Most Recent Events

    • 03 May 2017 Treatment arms has been changed from 1 to 2. Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines has been added and primary endpoint has changed from Proportion of patients with response to efficacy of Ruxolitinib and BAT as compared to BAT alone at day 28 after treatment start. patients number increases and official title also amended.
    • 03 May 2017 Planned number of patients changed from 92 to 148.
    • 03 May 2017 Planned End Date changed from 1 Dec 2020 to 1 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top